What Okomera does

Okomera is a Paris-based functional precision medicine biotech founded in 2020 that builds miniaturized tumor-on-chip technology paired with AI imaging analysis to predict personalized cancer drug responses from patient-derived biopsies. Its core product, the Okomera Platform, uses droplet-based microfluidics to encapsulate patient-derived 3D organoids and spheroids, enabling automated screening of up to 800 conditions on 1,000 microtumors per batch with a turnaround of approximately one week and a minimum input of 50 cells — figures the company positions as 6x faster and 1000x lower in sample requirement than incumbent methods. The technology originates from research at Ecole Polytechnique and Institut Pasteur, and is being extended into CRISPR screening assays through a collaboration with CRCM Marseille funded by Bpifrance.

The company operates a B2B enterprise model targeting pharmaceutical and biotech drug developers for preclinical and target-identification studies, academic cancer research centers, and clinical oncologists for treatment-selection support. Revenue is generated through professional services for drug discovery (preclinical screening, CRISPR screening, T-cell potency testing) and recurring subscription-style clinical decision support for hospitals, with pricing opaque and provided on a quote basis. The company is venture-backed (≈€11.5M disclosed, including a December 2023 €10M round led by Resonance with Berkeley SkyDeck, Polytechnique Ventures, and SkyDeck Berkeley, plus a €1.5M Bpifrance grant in October 2024), employs 11–50 people, and operates from a single Paris headquarters with no disclosed commercial geographic footprint beyond France.

Strategic positioning rests on a tightly integrated stack of proprietary microfluidics, AI-driven image analysis, and access to tier-1 oncology partners (Institut Curie, Gustave Roussy, Cancer Research UK, UC Berkeley), combined with peer-reviewed scientific output (SLAS 2023 Ignite Award, publications in iScience, Nature Communications, Cell Reports, Science Advances). Distribution is direct enterprise sales with no disclosed resellers, and customer logos are not publicly named, implying an early commercial stage where validation partners double as reference accounts.

Name

Okomera

Legal name

OKOMERA

Website

https://okomera.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Okomera is a Paris-based biotech that combines miniaturized tumor-on-chip microfluidics with AI imaging to deliver personalized cancer drug-response testing from patient biopsies in under a week, serving pharmaceutical, biotech, academic, and clinical oncology customers.

Ownership category

akta.pro rank

Product category

Functional Precision Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Tumor-on-chip technology
• Precision medicine oncology
• Organoid drug screening
• Cancer drug discovery
• Microfluidics platform

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Discovery Services: Provides pharmaceutical and biotech companies with preclinical drug screening services using patient-derived organoids and spheroids to identify effective cancer treatments.
2. Clinical Decision Support: Offers personalized treatment intelligence services for clinicians to guide cancer treatment decisions based on individual patient drug response patterns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Okomera develops and operates a functional precision medicine platform that combines miniaturized tumor-on-chip microfluidic technology with AI imaging analysis to deliver rapid, personalized drug response testing from patient-derived biopsies. The platform serves pharmaceutical and biotech companies for preclinical drug screening and cancer research, and supports clinical oncologists with treatment selection intelligence, returning results in under one week from as few as 50 cells.

Product overview

Okomera offers a unified functional precision medicine platform for personalized cancer care. The core Okomera Platform combines miniaturized tumor-on-chip technology and AI imaging to transform complex tumor biological responses into actionable treatment intelligence. The platform enables clinicians and drug developers to test up to 800 different conditions on 1000 microtumors from patient-derived biopsies, delivering results in under a week with only 50 cells needed. Applications span drug development, preclinical studies, and clinical decision-making, covering use cases including CRISPR screening, T-Cell Potency testing, and drug screening.

Differentiator

Problem solved

Functional benefit

Products and services

• Okomera Platform Functional precision medicine platform combining miniaturized tumor-on-chip technology with AI imaging to test up to 800 conditions on 1000 microtumors from patient-derived biopsies, returning personalized drug response patterns in under one week from as few as 50 cells. Targeted at pharmaceutical and biotech drug developers, academic cancer researchers, and clinical oncology institutions for drug discovery, preclinical studies, and clinical decision-making applications including CRISPR screening, T-Cell Potency testing, and drug screening.
• Drug Discovery Services Preclinical drug screening services using patient-derived organoids and spheroids to help pharmaceutical and biotech companies identify effective cancer treatments, evaluate drug efficacy, and identify therapeutic targets with high-throughput microfluidic screening. Customers contract for project-based screening engagements on the Okomera Platform.
• Clinical Decision Support (Personalized Treatment Intelligence) Recurring personalized treatment intelligence service for clinicians and cancer centers that delivers patient-specific drug response patterns from biopsy material to guide cancer therapy selection and address the roughly 50% first-line treatment failure rate. Sold on a recurring basis to hospitals and clinical oncology institutions.

Quantifiable outcome

• 1-week turnaround from biopsy to treatment decision
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and major.

• CRCM (Centre de Recherche en Cancérologie de Marseille)coreStrategic or Co-development Partner · 21 October 2024Cancer research center in Marseille collaborating on the development of novel CRISPR screening assay for cancer drug discovery using microfluidics and AI integration.
• Ecole PolytechniquecoreStrategic or Co-development PartnerAcademic research partner contributing breakthrough science and technology foundations for Okomera's platform. Provides ongoing research collaboration and access to scientific expertise in microfluidics and bioengineering.
• Institut PasteurcoreStrategic or Co-development PartnerAcademic research partner providing foundational scientific research for Okomera's tumor-on-chip technology. Key source of breakthrough science in cancer biology and organoid research.
• Institut CuriecoreStrategic or Co-development PartnerLeading French cancer research center and university hospital. Strategic partner for clinical validation and research collaboration in oncology applications.
• Gustave Roussy Cancer CampuscoreStrategic or Co-development PartnerPremier European cancer research and treatment center. Strategic partner for clinical applications and validation of personalized medicine approaches.
• Cancer Research UKmajorStrategic or Co-development PartnerMajor UK-based cancer research charity and funder. Research partner for cancer biology studies and drug discovery applications.
• University of California, BerkeleymajorStrategic or Co-development PartnerUS academic partner for research collaboration in bioengineering and cancer technology applications.

Scale indicators7 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Mimetas: Dutch organ-on-chip company offering microfluidic 3D tissue models for drug discovery and toxicity screening. Closest direct competitor to Okomera in droplet-microfluidics and organoid-based drug response testing, serving the same pharma/biotech buyer set.
• Emulate: US organ-on-chip platform using microfluidic 'chips' to model human organ biology for pharmaceutical R&D. Comparable in combining microfluidic chips with biological assays and AI/ML readout for drug discovery, targeting similar enterprise pharma customers.
• CN Bio Innovations: UK-based organ-on-chip company with single- and multi-organ microphysiological systems used for drug discovery and disease modeling. Overlaps directly with Okomera in microfluidic platforms for preclinical drug screening and human-relevant disease models.
• InSphero: Swiss 3D organoid and spheroid screening company offering high-throughput in vitro models for drug discovery and safety assessment. Directly comparable to Okomera's use of patient-derived spheroids for drug response testing and preclinical applications.
• Hubrecht Organoid Technology (HUB): Dutch pioneer of adult stem cell-derived organoids, offering organoid biobanks and drug screening services. Comparable to Okomera in applying patient-derived organoids to functional precision medicine and oncology drug response prediction.

Broad incumbents

• Crown Bioscience: Global preclinical CRO offering oncology services including organoid and PDX drug screening for pharma/biotech customers. Comparable buyer set and oncology drug-discovery use cases, but broader portfolio including in vivo models and clinical CRO services.
• Tempus Labs: US precision oncology company combining molecular profiling, AI, and clinical data to support therapy selection in oncology. Overlaps with Okomera in AI-enabled personalized oncology decision support, but at much larger scale and with DNA/molecular rather than functional assay approaches.
• Foundation Medicine: Genomics-driven oncology diagnostics company (Roche subsidiary) providing molecular profiling to guide cancer therapy. Comparable in serving the personalized oncology therapy-selection use case that Okomera targets, though via molecular rather than functional assays.

Emerging players

• CytoReason: Israel-based AI drug discovery company using machine-learning models trained on proprietary biological data to support pharma R&D and target identification. Comparable emerging player applying AI to accelerate oncology drug discovery, with potential to converge with functional assay providers like Okomera.

Regional players

• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutics for oncology, with adjacent interest in functional cancer biology. Comparable in operating in the European precision oncology ecosystem and engaging the same pharma and academic partners as Okomera, though focused on therapeutic development rather than screening platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Okomera1

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okomera